Litigation Details for Gilead Sciences v. Sigmapharm Labs (Fed. Cir. 2014)
✉ Email this page to a colleague
Gilead Sciences v. Sigmapharm Labs (Fed. Cir. 2014)
| Docket | ⤷ Sign Up | Date Filed | 2014-05-05 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 6,451,340 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Gilead Sciences v. Sigmapharm Labs
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Gilead Sciences v. Sigmapharm Labs (Fed. Cir. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-07-10 | 25 | Sue for infringement of U.S. Patent No. 6,451,340 (“the ’340 patent”) on or about March 15, 2013, and…United States Patent No. 6,451,340…………….…………….…….A37-A91 4. United States Patent No. 5,663,159…… and U.S. Patent No. 6,451,340 (“the ’340 patent”). Gilead sells AD tablets under the brand name HEPSERA… United States Patent No. 6,451,340 A37…OF THIS OFFICE OF: U.S. PATENT: 6,451,340 ISSUE DATE: September 17, 2002 | External link to document | |
| 2014-08-21 | 31 | position with respect to U.S. Patent No. 6,451,340 (the “’340 Patent”) was anything other than a …infringe the ’159 Patent or the ’340 Patent, and alleging that the ’159 Patent was invalid. On …infringing claims of U.S. Patent Nos. 6,848,072 (the ’072 patent), 7,028,244 (the ’244 patent), …listed United States patents assigned or licensed to Gilead, namely ’159 Patent claims AD and expires…of certain asserted claims of the ’159 Patent (i.e., the patent covering, inter alia, the compound | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
